Goodrx Holdings Inc
$ 2.23
3.72%
14 Apr - close price
- Market Cap 736,535,000 USD
- Current Price $ 2.23
- High / Low $ 2.26 / 2.15
- Stock P/E 23.89
- Book Value 1.81
- EPS 0.09
- Next Earning Report 2026-05-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.05 %
- ROE 0.05 %
- 52 Week High 5.81
- 52 Week Low 1.77
About
GoodRx Holdings, Inc. provides information and tools that allow consumers to compare prices and save when buying prescription drugs in the United States. The company is headquartered in Santa Monica, California.
Analyst Target Price
$2.82
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-25 | 2025-11-04 | 2025-08-06 | 2025-05-07 | 2025-02-26 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-02-29 | 2023-11-09 | 2023-08-09 | 2023-05-10 |
| Reported EPS | 0.09 | 0.08 | 0.09 | 0.09 | 0.09 | 0.08 | 0.08 | 0.08 | 0.08 | 0.06 | 0.07 | 0.07 |
| Estimated EPS | 0.0917 | 0.09 | 0.1 | 0.0957 | 0.0959 | 0.09 | 0.09 | 0.08 | 0.07 | 0.06 | 0.06 | 0.06 |
| Surprise | -0.0017 | -0.01 | -0.01 | -0.0057 | -0.0059 | -0.01 | -0.01 | 0 | 0.01 | 0 | 0.01 | 0.01 |
| Surprise Percentage | -1.8539% | -11.1111% | -10% | -5.9561% | -6.1522% | -11.1111% | -11.1111% | 0% | 14.2857% | 0% | 16.6667% | 16.6667% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-06 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.03 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: GDRX
2026-04-04 17:39:12
GoodRx Holdings, Inc. (NASDAQ: GDRX) has filed an 8-K current report with the SEC, announcing the resignation of director Ian T. Clark and a subsequent board realignment. CEO Wendy Barnes was reclassified from Class I to Class III director to balance the board's classes. The company stated the resignation was not due to disagreements, but investors are advised to monitor such governance changes as they can impact shareholder sentiment and potentially share price.
2026-04-04 11:40:38
GoodRx Holdings Inc. (NASDAQ:GDRX) announced changes to its board of directors following the resignation of Ian T. Clark. Wendy Barnes, the CEO, President, and Director, was transferred from Class I to Class III to rebalance the board's membership, with her term now expiring at the 2026 annual meeting. These changes ensure the board now has three directors in each class, and the company clarified that Barnes's service remains uninterrupted for all other purposes.
2026-04-03 21:10:57
GoodRx Holdings announced changes to its board of directors following the resignation of Ian T. Clark. Wendy Barnes, CEO, President, and Director, was transferred from Class I to Class III to balance the board's classes. The company also recently reported Q4 2025 earnings and updated financial guidance, leading to revised price targets from analysts and the resignation of its Chief Accounting Officer.
2026-04-03 20:09:35
GoodRx announced that Ian T. Clark resigned from its Board of Directors, effective March 31, 2026. Following his departure, Wendy Barnes was reclassified and appointed to Class III of the Board, effective April 1, 2026, to rebalance board membership. Her new term will expire in 2026, shifting from her previous Class I position.
2026-04-03 20:09:35
GoodRx Holdings, Inc. (GDRX) announced governance changes to its Board of Directors following the resignation of Ian T. Clark on March 31, 2026. To rebalance the director classes, Wendy Barnes resigned as a Class I director and was immediately re-elected as a Class III director, with her board service considered uninterrupted. The Board now has an equal balance of three directors in each of Classes I, II, and III.
2026-03-30 15:09:18
The Vanguard Group has filed an amendment to its Schedule 13G/A, reporting zero beneficial ownership (0%) of GoodRx Holdings Inc. common stock as of March 13, 2026. This change follows an internal realignment on January 12, 2026, where certain Vanguard subsidiaries, in accordance with SEC Release No. 34-39538, began reporting their beneficial ownership separately. The filing was signed by Ashley Grim, Head of Global Fund Administration, on March 27, 2026.
